Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>Events>This Event
  Events - October 2014


Translational Regenerative Medicine Congress 2014

21 Oct 2014 - 22 Oct 2014 - Radisson Blu Hotel, Leipzig, Germany



Bookmark and Share


SELECTBIO is hosting the Translational Regenerative Medicine Congress which is organized by the Translational Centre for Regenerative Medicine (TRM) of the Leipzig University. This indication-related congress brings together delegates from clinic, leading pharmaceutical companies and academia from around the world focusing on innovative treatment strategies in the field of regenerative medicine.

The congress provides presentations and panel discussions focusing on novel diagnostic and therapeutic methods of regenerative medicine. For practitioners, this translation-oriented event offers the exceptional opportunity to gain knowledge about new treatment concepts in regenerative medicine. For researchers, this event offers a platform to promote new therapeutic approaches in regenerative medicine and to create a business platform.

The Translational Centre for Regenerative Medicine (TRM) based in Leipzig, Germany, develops novel diagnostic and therapeutic methods of regenerative medicine and enables the rapid transfer of results into medical practice. In the framework of interdisciplinary research projects the TRM bridges the gap between basic research, clinical application and commercial exploitation.

Its Service portfolio comprises Research and Development Services, Non-clinical Safety Testing, Preclinical Services and Continuing Education and Consulting. TRM is an experienced organizer of international conferences and co-organizes the World Conference on Regenerative Medicine, one of the biggest conferences in the field of regenerative medicine.



Further information
Scientific News
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
New Material Forges the Way for 'Stem Cell Factories'
Researchers have discovered the first fully synthetic substrate with potential to grow billions of stem cells. The researchcould forge the way for the creation of 'stem cell factories' - the mass production of human embryonic (pluripotent) stem cells.
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
'Google Maps' for the Body
Scientists have revealed research that uses previously top-secret technology to zoom through the human body down to the level of a single cell that could be a game-changer for medicine.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!